Account
News

PMA Insights: Week 7

17/02/2023
  • CEPs Annual Report indicates reduced time to market access
  • The FDA’s Biosimilar User Fee Amendments III (BsUFA III)
15022023-News-Digest-Wk-7Download

Author:

Amy Rudd, ACIM
About the Author

Article Tags

Biosimilars Funding Gene Therapy & ATMPs HTA PMA Trends Pricing

Share this article

Related articles

Articles
28.01.2026
If You’re a Market Access Lead in 2026: How to N...

In 2026, U.S. policy shifts will link domestic US prices to internatio...

Read more
Webinar
26.01.2026
Top Market Access Trends for 2026

As Market Access continues to evolve amid policy reform, pricing pressure, and increasing evidence e...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch